期刊
JOURNAL OF VIROLOGY
卷 75, 期 5, 页码 2368-2376出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.75.5.2368-2376.2001
关键词
-
类别
资金
- NCI NIH HHS [U19 CA072108, U19 CA72108-02, R01 CA72631-01] Funding Source: Medline
Recently, self-replicating and self-limiting RNA vaccines (RNA replicons) have emerged as an important form of nucleic acid vaccines. Self-replicating RNA eventually causes lysis of transfected cells and does not raise the concern associated with naked DNA vaccines of integration into the host genome. This is particularly important for development of vaccines targeting proteins that are potentially oncogenic. However, the potency of RNA replicons is significantly limited by their lack of intrinsic ability to spread in vivo. The herpes simplex virus type 1 protein VP22 has demonstrated the remarkable property of intercellular transport and provides the opportunity to enhance RNA replicon vaccine potency. We therefore created a novel fusion of VP22 with a model tumor antigen, human papillomavirus type 16 E7, in a Sindbis virus RNA replicon vector, The linkage of VP22 with E7 resulted in a significant enhancement of E7-specific CD8(+) T-cell activities in vaccinated mice and converted a less effective RNA replicon vaccine into one with significant potency against E7-expressing tumors. These results indicate that fusion of VP22 to an antigen gene may greatly enhance the potency of RNA replicon vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据